US4775624A
(en)
*
|
1985-02-08 |
1988-10-04 |
Eli Lilly And Company |
Vectors and compounds for expression of human protein C
|
US5981216A
(en)
*
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
US4770999A
(en)
*
|
1985-04-22 |
1988-09-13 |
Genetics Institute, Inc. |
High yield production of active Factor IX
|
US4959318A
(en)
*
|
1985-06-27 |
1990-09-25 |
Zymogenetics, Inc. |
Expression of protein C
|
US4968626A
(en)
*
|
1985-08-15 |
1990-11-06 |
Board Of Reagents Of The University Of Washington |
DNA sequence coding for protein C
|
EP0215548B2
(en)
*
|
1985-06-27 |
1998-01-07 |
Zymogenetics, Inc. |
Expression of protein C
|
US5516650A
(en)
*
|
1985-06-27 |
1996-05-14 |
Zymogenetics, Inc. |
Production of activated protein C
|
USRE38981E1
(en)
*
|
1985-08-15 |
2006-02-14 |
Board Of Regents Of The University Of Washington |
DNA sequence coding for protein C
|
US5618715A
(en)
*
|
1985-12-20 |
1997-04-08 |
Oncogen Limited Partnership |
Oncostatin M and novel compositions having anti-neoplastic activity
|
GB8607502D0
(en)
*
|
1986-03-26 |
1986-04-30 |
Antibioticos Sa |
Penicillium chrysogenum
|
CA1340384C
(fr)
*
|
1986-04-09 |
1999-02-09 |
Eli Lilly And Company |
Method of using eukaryotic expression vectors comprising the bk virus enhancer
|
US5550036A
(en)
*
|
1986-04-09 |
1996-08-27 |
Eli Lilly And Company |
Method for co-amplification of human protein C genes in human cells
|
JPS63105675A
(ja)
*
|
1986-10-23 |
1988-05-10 |
Green Cross Corp:The |
ヒトウロキナ−ゼの製造方法
|
AU1187588A
(en)
*
|
1987-01-15 |
1988-08-10 |
Codon Genetic Engineering Laboratories |
Tandem gene eukaryotic expression vectors
|
JPH03501921A
(ja)
*
|
1987-05-18 |
1991-05-09 |
インテグレイテッド・ジェネティクス・インク |
改良タンパク質分子、並びにその製造及び活性化方法
|
DK260987D0
(da)
*
|
1987-05-22 |
1987-05-22 |
Nordisk Gentofte |
Fremgangsmaade til fremstilling af et humant protein samt dna-sekvens til anvendelse ved udoevelse af fremgangsmaaden
|
JPS6445398A
(en)
*
|
1987-08-13 |
1989-02-17 |
Kowa Co |
Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
|
US5084274A
(en)
*
|
1987-11-17 |
1992-01-28 |
Scripps Clinic And Research Foundation |
Inhibition of arterial thrombotic occlusion or thromboembolism
|
IL87171A
(en)
*
|
1987-11-23 |
1995-08-31 |
Monsanto Co |
ANDC of human tissue factor inhibitor
|
US4992373A
(en)
*
|
1987-12-04 |
1991-02-12 |
Eli Lilly And Company |
Vectors and compounds for direct expression of activated human protein C
|
US5196322A
(en)
*
|
1987-12-28 |
1993-03-23 |
Eli Lilly And Company |
Vectors and compounds for expression of zymogen forms of human protein C
|
ZA889497B
(en)
*
|
1987-12-28 |
1990-08-29 |
Lilly Co Eli |
Vectors and compounds for expression of zymogen forms of human protein c
|
US5009889A
(en)
*
|
1987-12-31 |
1991-04-23 |
Oklahoma Medical Research Foundation |
Treatment of dysfunctional vascular endothelium using activated protein C
|
JPH01285196A
(ja)
*
|
1988-05-11 |
1989-11-16 |
Chisso Corp |
発光蛋白エクオリンの製造法
|
GB8819607D0
(en)
*
|
1988-08-17 |
1988-09-21 |
Wellcome Found |
Novel combination
|
CA1332049C
(en)
*
|
1988-10-07 |
1994-09-20 |
Eli Lilly And Company |
Eukaryotic expression
|
US5047335A
(en)
*
|
1988-12-21 |
1991-09-10 |
The Regents Of The University Of Calif. |
Process for controlling intracellular glycosylation of proteins
|
US5147638A
(en)
*
|
1988-12-30 |
1992-09-15 |
Oklahoma Medical Research Foundation |
Inhibition of tumor growth by blockade of the protein C system
|
US6423313B1
(en)
*
|
1988-12-30 |
2002-07-23 |
Oklahoma Medical Research Foundation |
Inhibition of tumor growth by blockade of the protein C system
|
US5120537A
(en)
*
|
1989-06-14 |
1992-06-09 |
Oklahoma Medical Research Foundation |
Factor xa based anticoagulant compositions
|
SE464135B
(sv)
*
|
1989-07-14 |
1991-03-11 |
Kabivitrum Ab |
Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
|
DK0506821T3
(da)
*
|
1989-12-29 |
1998-03-30 |
Zymogenetics Inc |
Hybridt protein C
|
US5358932A
(en)
*
|
1989-12-29 |
1994-10-25 |
Zymogenetics, Inc. |
Hybrid protein C
|
US5225537A
(en)
*
|
1989-12-29 |
1993-07-06 |
Zymogenetics, Inc. |
Methods for producing hybrid phospholipid-binding proteins
|
ATE180834T1
(de)
*
|
1990-01-29 |
1999-06-15 |
Zymogenetics Inc |
Antikoagulierende proteine
|
IL97312A
(en)
|
1990-02-23 |
1999-01-26 |
Lilly Co Eli |
A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
|
US5270178A
(en)
*
|
1990-02-23 |
1993-12-14 |
Eli Lilly And Company |
Vectors and compounds for expression of zymogen forms of human protein C
|
IL97311A0
(en)
*
|
1990-02-23 |
1992-05-25 |
Lilly Co Eli |
Vectors and compounds for expression of glycosylation mutants of human protein c
|
US5571786A
(en)
*
|
1990-08-16 |
1996-11-05 |
Immuno Aktiengesellschaft |
Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
|
US5831141A
(en)
*
|
1991-01-11 |
1998-11-03 |
United States Of America As Represented By The Department Of Health And Human Services |
Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
|
ATE211177T1
(de)
*
|
1991-01-11 |
2002-01-15 |
American Nat Red Cross |
Expression von aktivem menschlichem protein c im milchdrüsengewebe transgener tiere
|
US6262336B1
(en)
|
1991-01-11 |
2001-07-17 |
American Red Cross |
Expression of a heterologous protein C in mammary tissue of transgenic animals using a long whey acidic protein promoter
|
US5965789A
(en)
*
|
1991-01-11 |
1999-10-12 |
American Red Cross |
Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
|
US5833982A
(en)
|
1991-02-28 |
1998-11-10 |
Zymogenetics, Inc. |
Modified factor VII
|
US5861374A
(en)
*
|
1991-02-28 |
1999-01-19 |
Novo Nordisk A/S |
Modified Factor VII
|
US5817788A
(en)
*
|
1991-02-28 |
1998-10-06 |
Zymogenetics, Inc. |
Modified factor VII
|
US5997864A
(en)
|
1995-06-07 |
1999-12-07 |
Novo Nordisk A/S |
Modified factor VII
|
US5788965A
(en)
*
|
1991-02-28 |
1998-08-04 |
Novo Nordisk A/S |
Modified factor VII
|
AT397615B
(de)
*
|
1991-05-14 |
1994-05-25 |
Immuno Ag |
Arzneimittel enthaltend protein c
|
US6039944A
(en)
*
|
1992-02-28 |
2000-03-21 |
Zymogenetics, Inc. |
Modified Factor VII
|
MY110664A
(en)
*
|
1992-05-21 |
1999-01-30 |
Lilly Co Eli |
Protein c derivatives
|
DE4320294A1
(de)
*
|
1993-06-18 |
1994-12-22 |
Immuno Ag |
Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
|
CN1103815C
(zh)
*
|
1993-11-12 |
2003-03-26 |
吉里德科学公司 |
凝血酶突变体
|
US7060484B1
(en)
|
1993-11-12 |
2006-06-13 |
Gilead Sciences, Inc. |
Polypeptides and coagulation therapy
|
US5618714A
(en)
*
|
1993-12-15 |
1997-04-08 |
Eli Lilly And Company |
Methods for producing protein C
|
WO1995024929A2
(en)
|
1994-03-15 |
1995-09-21 |
Brown University Research Foundation |
Polymeric gene delivery system
|
AU2467395A
(en)
*
|
1994-05-04 |
1995-11-29 |
Board Of Trustees Of The University Of Arkansas, The |
Novel ophthalmologic uses of protein c
|
AT403167B
(de)
*
|
1994-11-14 |
1997-11-25 |
Immuno Ag |
Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
|
US6017697A
(en)
|
1994-11-14 |
2000-01-25 |
Eli Lilly And Company |
Excitatory amino acid receptor protein and related nucleic acid compounds
|
US6211142B1
(en)
*
|
1995-03-10 |
2001-04-03 |
Genentech, Inc. |
Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
|
BRPI9712348C8
(pt)
|
1996-10-16 |
2020-04-22 |
Zymogenetics Inc |
vetor de expressão, célula de bactéria ou levedura transformada ou transfectada, processo para produzir um polipeptídeo homólogo de fgf, composição farmacêutica, e, processos para estimular ex vivo células progenitoras de miócitos ou miócitos
|
WO1998020118A1
(en)
*
|
1996-11-08 |
1998-05-14 |
Oklahoma Medical Research Foundation |
Modified protein c and methods of use thereof
|
US20060127387A1
(en)
*
|
1997-04-22 |
2006-06-15 |
Zikria Bashir A |
Compositions based on polysaccharides and protein C and methods of using the same for preventing and treating sepsis and other conditions
|
AR015598A1
(es)
*
|
1997-04-28 |
2001-05-16 |
Lilly Co Eli |
FORMULACIoN LIOFILIZADA QUE COMPRENDE PROTEíNA C ACTIVADA, SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO Y FORMA DE DOSIS UNITARIA QUE LA COMPRENDE.
|
US6630137B1
(en)
*
|
1997-04-28 |
2003-10-07 |
Eli Lilly And Company |
Activated protein C formulations
|
AU741983B2
(en)
*
|
1997-06-05 |
2001-12-13 |
Eli Lilly And Company |
Methods for treating thrombotic disorders
|
HUP0001237A3
(en)
*
|
1997-10-20 |
2002-01-28 |
Lilly Co Eli |
Methods for treating vascular disorders
|
US6815533B1
(en)
|
1998-07-31 |
2004-11-09 |
Eli Lilly And Company |
Cryogranulation of activated protein C
|
CA2347250A1
(en)
|
1998-10-22 |
2000-04-27 |
Sau-Chi Betty Yan |
Methods for treating sepsis
|
JP2002529515A
(ja)
|
1998-11-13 |
2002-09-10 |
イーライ・リリー・アンド・カンパニー |
ヘパリンにより誘発される血小板減少症の処置法
|
ATE235915T1
(de)
|
1998-11-20 |
2003-04-15 |
Lilly Co Eli |
Behandlung von hämorrhagischem virusfieber mit protein c
|
ES2192874T3
(es)
|
1998-11-23 |
2003-10-16 |
Lilly Co Eli |
Proteina c para el tratamiento de la enfermedad de la celula con anemia hepatica y talasemia.
|
CA2391651A1
(en)
*
|
1999-11-19 |
2001-05-25 |
Eli Lilly And Company |
Protein c derivatives
|
US7204981B2
(en)
*
|
2000-03-28 |
2007-04-17 |
Eli Lilly And Company |
Methods of treating diseases with activated protein C
|
JP2004511428A
(ja)
|
2000-05-24 |
2004-04-15 |
イーライ・リリー・アンド・カンパニー |
凝固亢進状態を処置するための製剤および方法
|
CA2425221A1
(en)
*
|
2000-10-18 |
2002-04-25 |
Maxygen Aps |
Protein c or activated protein c-like molecules
|
US6933367B2
(en)
|
2000-10-18 |
2005-08-23 |
Maxygen Aps |
Protein C or activated protein C-like molecules
|
WO2002085117A1
(en)
*
|
2001-04-24 |
2002-10-31 |
Eisai Co., Ltd. |
Methods and compositions for preventing and treating septic shock and endotoxemia
|
WO2003007686A2
(en)
*
|
2001-07-19 |
2003-01-30 |
Dmi Biosciences, Inc. |
Use of copper chelators to inhibit the inactivation of protein c
|
US20030073636A1
(en)
*
|
2001-09-19 |
2003-04-17 |
Oklahoma Medical Research Foundation |
Method of treating diabetes
|
WO2003024398A2
(en)
|
2001-09-19 |
2003-03-27 |
Oklahoma Medical Research Foundation |
Treatment of sepsis with tafi
|
US7308303B2
(en)
*
|
2001-11-01 |
2007-12-11 |
Advanced Bionics Corporation |
Thrombolysis and chronic anticoagulation therapy
|
AU2003213146A1
(en)
*
|
2002-03-08 |
2003-09-22 |
Eli Lilly And Company |
Activated protein c formulations
|
WO2004056309A2
(en)
|
2002-12-05 |
2004-07-08 |
Socratech L.L.C. |
Neuroprotective activity of activated protein c is independent of its anticoagulant activity
|
ES2400853T3
(es)
*
|
2002-12-27 |
2013-04-12 |
The Chemo-Sero-Therapeutic Research Institute |
Agente para mejorar la esperanza de vida en el tratamiento de una neoplasia
|
US20070142272A1
(en)
*
|
2003-01-24 |
2007-06-21 |
Zlokovic Berislav V |
Neuroprotective activity of activated protein c independent of its anticoagulant activity
|
KR101284884B1
(ko)
*
|
2003-07-08 |
2013-07-10 |
더 스크립스 리서치 인스티튜트 |
정상의 세포보호 활성 및 저하된 항응고 활성을 지닌활성화 단백질 c 변이체
|
US9192657B2
(en)
*
|
2003-07-08 |
2015-11-24 |
The Scripps Research Institute |
Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
|
CN102250861A
(zh)
|
2004-02-13 |
2011-11-23 |
诺维信公司 |
蛋白酶变体
|
US20080305100A1
(en)
*
|
2004-07-23 |
2008-12-11 |
Zlokovic Berislav V |
Activated Protein C Inhibits Undesirable Effects of Plasminogen Activator in the Brain
|
CA2612859A1
(en)
*
|
2005-06-23 |
2006-12-28 |
The University Of British Columbia |
Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
|
EP1896059B1
(en)
*
|
2005-06-24 |
2012-12-19 |
Drugrecure ApS |
Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract
|
CA2654761A1
(en)
*
|
2006-06-09 |
2007-12-13 |
The University Of British Columbia |
Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
|
WO2008048646A1
(en)
*
|
2006-10-18 |
2008-04-24 |
Socratech L.L.C. |
Use of human protein c with altered glycosylation and sialic acid content as a medicament
|
WO2008073603A2
(en)
*
|
2006-10-31 |
2008-06-19 |
The Scripps Research Institute |
Dosing regimen of activated protein c and variants having reduced anticoagulant activity
|
WO2009089620A1
(en)
*
|
2008-01-15 |
2009-07-23 |
The Universityof British Columbia |
Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
|
RU2469093C2
(ru)
*
|
2008-12-19 |
2012-12-10 |
Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") |
ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pCID-PROC, КОДИРУЮЩАЯ ПРОТЕИН С ЧЕЛОВЕКА, И КЛЕТОЧНАЯ ЛИНИЯ DG-CID-PROC-1, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ПРОТЕИН С ЧЕЛОВЕКА
|
WO2012068519A2
(en)
|
2010-11-19 |
2012-05-24 |
Sirius Genomics Inc. |
Markers associated with response to activated protein c administration, and uses thereof
|
IN2014DN11181A
(da)
|
2012-07-04 |
2015-10-02 |
Univ Sydney |
|
US20170042982A1
(en)
|
2014-04-16 |
2017-02-16 |
Zz Biotech Llc |
Treatment of abnormal cutaneous scarring
|
WO2023119230A1
(en)
|
2021-12-22 |
2023-06-29 |
L'oreal |
Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
|